Targeting Antiapoptotic Genes Upregulated by Androgen Withdrawal Using Antisense Oligodeoxynucleotides to Enhance Androgen-and Chemo-Sensitivity in Prostate Cancer
Androgen withdrawal is the only effective form of systemic therapy for men with advanced disease, producing symptomatic and/or objective response in 80% of patients. Unfortunately, androgen independent (AI) progression and death occurs within a few years in the majority of these cases (6). Prostate cancer is highly chemoresistant, with objective response rates of 10% and no demonstrated survival benefit (28). Hormone refractory prostate cancer (HRPC) is therefore the main obstacle to improving the survival and quality of life in patients with advanced disease, and novel therapeutic strategies that target the molecular basis of androgen and chemoresistance are required.
KeywordsProstate Cancer LNCaP Cell Human Prostate Cancer Hormone Refractory Prostate Cancer Androgen Ablation
Unable to display preview. Download preview PDF.
- 1.Boise, L., M. Gonzalez-Garcia, C. Postema, L. Ding, T. Lindsten, L. Turka, 1993. bcl-x, a bc1–2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74: 597–608.Google Scholar
- 8.Gleave, M. E. and J. T. Hsieh. 1997. Animal models in prostate cancer, in The Principles and Practice of Genitourinary Oncology ( Raghavan, D., H. Scher, S. Leibel, and P. H. Lange, eds.), Philadelphia: J B Lippincott Co., Philadelphia, pp. 367–378.Google Scholar
- 11.Halder, S., A. Basu, and C. M. Croce. 1997. Bc12 is the guardian of microtubule integrity. Cancer Res. 57: 229–233.Google Scholar
- 15.Jansen, B., H. Schlagbauer-Wadi, B. D. Brown, R. N. Bryan, A. van Elsas, and M. Muller. 1998. bc1–2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat. Med 4: 232–234.Google Scholar
- 21.Miyaki, H., A. Tolcher, and M. E. Gleave. 2000. Antisense Bcl-2 oligodeoxynucleotides enhance taxol chemosensitivity and synergistically delays progression to androgen-independence after castration in the androgen dependent Shionogi tumor model. JNCI 92: 34–41.Google Scholar
- 27.Patterson, R., M. Gleave, E. Jones, J. Zubovits, S. L. Goldenberg, and L. D. Sullivan. 1999. Immunohistochemical analysis of radical prostatectomy specimens after 8 months of neoadjuvant hormone therapy. Mol. Urol 3: 277–286.Google Scholar
- 33.Sato, N., M. D. Sadar, N. Bruchovsky, F. Saatcioglu, P. S. Rennie, S. Sato, 1997. Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between androgen receptor and AP- lc-Jun in the human prostate cancer cell line LN CaP. J. Biol. Chem. 272: 17,485–17, 494.Google Scholar
- 38.Zieger, A., G. H. Luedke, D. Fabbro, K.-H. Altman, R. A. Stahel, and U. ZangemeisterWittke. 1997. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the BcI-2 coding sequence. JNCI 89: 1027–1036.Google Scholar